Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PONATINIB Cause Chronic obstructive pulmonary disease? 22 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Chronic obstructive pulmonary disease have been filed in association with PONATINIB (Iclusig). This represents 0.2% of all adverse event reports for PONATINIB.

22
Reports of Chronic obstructive pulmonary disease with PONATINIB
0.2%
of all PONATINIB reports
5
Deaths
14
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From PONATINIB?

Of the 22 reports, 5 (22.7%) resulted in death, 14 (63.6%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PONATINIB. However, 22 reports have been filed with the FAERS database.

What Other Side Effects Does PONATINIB Cause?

Death (1,735) Off label use (1,071) Product dose omission issue (817) Fatigue (687) Rash (639) Headache (553) Pyrexia (542) Nausea (466) Hospitalisation (459) Constipation (435)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which PONATINIB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

PONATINIB vs PONATINIB\PONATINIB PONATINIB vs PONESIMOD PONATINIB vs PORACTANT ALFA PONATINIB vs PORFIMER PONATINIB vs POSACONAZOLE

Related Pages

PONATINIB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease PONATINIB Demographics